ANCO - April 2026

April 2026

03/31/2026 10:08 AM | Anonymous

Coding and Reimbursement Updates

This Month’s E-Reiumbursement Newsletter from Bobbi Buell for March 31, 2026

Corporate Member News

FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer

Loading testimonials…

Apply to Become a Member

Practice and Professional Resources
Patient and Reimbursement Assistance Programs
Search Job Board
ANCO Member Directory
Corporate Member Directory
Oncology News & Updates
Update Profile
LOGOUT

About Us
Membership
Advocacy
Job Board
Clinical Trials

Member Portal
Meetings
Contact Us
Sitemap

4225 Solano Ave, #764
Napa, CA 94558
Phone (415) 472-3960